vs
西蒙地产集团（ELS）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
西蒙地产集团的季度营收约是Orthofix Medical Inc.的1.8倍（$397.6M vs $219.9M），西蒙地产集团同比增速更快（2.7% vs 2.0%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 2.3%）
西蒙地产集团是美国头部房地产投资信托企业，投资范围涵盖购物中心、奥特莱斯及社区生活中心等商业地产业态，是美国规模最大的购物中心持有方，总部位于印第安纳州印第安纳波利斯，截至2024年12月末共持有232处物业权益。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ELS vs OFIX — 直观对比
营收规模更大
ELS
是对方的1.8倍
$219.9M
营收增速更快
ELS
高出0.7%
2.0%
两年增速更快
OFIX
近两年复合增速
2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $397.6M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | 2.7% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $0.56 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ELSOFIX
| Q1 26 | $397.6M | — | ||
| Q4 25 | $373.9M | $219.9M | ||
| Q3 25 | $393.3M | $205.6M | ||
| Q2 25 | $376.9M | $203.1M | ||
| Q1 25 | $387.3M | $193.6M | ||
| Q4 24 | $372.3M | $215.7M | ||
| Q3 24 | $387.3M | $196.6M | ||
| Q2 24 | $380.0M | $198.6M |
净利润ELSOFIX
| Q1 26 | — | — | ||
| Q4 25 | $103.8M | $-2.2M | ||
| Q3 25 | $100.4M | $-22.8M | ||
| Q2 25 | $83.5M | $-14.1M | ||
| Q1 25 | $114.4M | $-53.1M | ||
| Q4 24 | $100.6M | $-29.1M | ||
| Q3 24 | $86.9M | $-27.4M | ||
| Q2 24 | $82.1M | $-33.4M |
毛利率ELSOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率ELSOFIX
| Q1 26 | — | — | ||
| Q4 25 | 26.5% | 0.2% | ||
| Q3 25 | 25.1% | -8.3% | ||
| Q2 25 | 22.3% | -7.9% | ||
| Q1 25 | 28.3% | -25.2% | ||
| Q4 24 | 27.2% | -5.3% | ||
| Q3 24 | 21.4% | -9.6% | ||
| Q2 24 | 21.5% | -12.5% |
净利率ELSOFIX
| Q1 26 | — | — | ||
| Q4 25 | 27.8% | -1.0% | ||
| Q3 25 | 25.5% | -11.1% | ||
| Q2 25 | 22.2% | -6.9% | ||
| Q1 25 | 29.5% | -27.4% | ||
| Q4 24 | 27.0% | -13.5% | ||
| Q3 24 | 22.4% | -13.9% | ||
| Q2 24 | 21.6% | -16.8% |
每股收益（稀释后）ELSOFIX
| Q1 26 | $0.56 | — | ||
| Q4 25 | $0.52 | $-0.05 | ||
| Q3 25 | $0.50 | $-0.57 | ||
| Q2 25 | $0.42 | $-0.36 | ||
| Q1 25 | $0.57 | $-1.35 | ||
| Q4 24 | $0.51 | $-0.76 | ||
| Q3 24 | $0.44 | $-0.71 | ||
| Q2 24 | $0.42 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $450.0M |
| 总资产 | $5.7M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ELSOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M |
总债务ELSOFIX
| Q1 26 | — | — | ||
| Q4 25 | $3.3B | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | $3.2B | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益ELSOFIX
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $450.0M | ||
| Q3 25 | $1.8B | $442.5M | ||
| Q2 25 | $1.7B | $458.3M | ||
| Q1 25 | $1.7B | $458.3M | ||
| Q4 24 | $1.7B | $503.1M | ||
| Q3 24 | $1.4B | $525.9M | ||
| Q2 24 | $1.4B | $546.0M |
总资产ELSOFIX
| Q1 26 | $5.7M | — | ||
| Q4 25 | $5.7B | $850.6M | ||
| Q3 25 | $5.7B | $832.6M | ||
| Q2 25 | $5.7B | $837.2M | ||
| Q1 25 | $5.6B | $823.1M | ||
| Q4 24 | $5.6B | $893.3M | ||
| Q3 24 | $5.6B | $867.9M | ||
| Q2 24 | $5.6B | $882.0M |
负债/权益比ELSOFIX
| Q1 26 | — | — | ||
| Q4 25 | 1.91× | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | 1.84× | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ELSOFIX
| Q1 26 | — | — | ||
| Q4 25 | $571.1M | $27.7M | ||
| Q3 25 | $147.0M | $12.4M | ||
| Q2 25 | $131.3M | $11.6M | ||
| Q1 25 | $193.4M | $-18.4M | ||
| Q4 24 | $596.7M | $23.7M | ||
| Q3 24 | $149.5M | $11.7M | ||
| Q2 24 | $143.1M | $9.0M |
自由现金流ELSOFIX
| Q1 26 | — | — | ||
| Q4 25 | $334.1M | $16.8M | ||
| Q3 25 | $75.7M | $2.5M | ||
| Q2 25 | $71.8M | $4.5M | ||
| Q1 25 | $148.2M | $-25.1M | ||
| Q4 24 | $355.4M | $15.2M | ||
| Q3 24 | $91.1M | $6.3M | ||
| Q2 24 | $80.6M | $-360.0K |
自由现金流率ELSOFIX
| Q1 26 | — | — | ||
| Q4 25 | 89.4% | 7.6% | ||
| Q3 25 | 19.3% | 1.2% | ||
| Q2 25 | 19.1% | 2.2% | ||
| Q1 25 | 38.3% | -13.0% | ||
| Q4 24 | 95.5% | 7.0% | ||
| Q3 24 | 23.5% | 3.2% | ||
| Q2 24 | 21.2% | -0.2% |
资本支出强度ELSOFIX
| Q1 26 | — | — | ||
| Q4 25 | 63.4% | 4.9% | ||
| Q3 25 | 18.1% | 4.8% | ||
| Q2 25 | 15.8% | 3.5% | ||
| Q1 25 | 11.7% | 3.5% | ||
| Q4 24 | 64.8% | 4.0% | ||
| Q3 24 | 15.1% | 2.7% | ||
| Q2 24 | 16.5% | 4.7% |
现金转化率ELSOFIX
| Q1 26 | — | — | ||
| Q4 25 | 5.50× | — | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.57× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 5.93× | — | ||
| Q3 24 | 1.72× | — | ||
| Q2 24 | 1.74× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ELS
| Rental income | $339.0M | 85% |
| Other | $37.2M | 9% |
| Annual membership subscriptions | $18.3M | 5% |
| Membership upgrade revenue | $3.1M | 1% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
